• Users Online: 114
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2022  |  Volume : 17  |  Issue : 4  |  Page : 1023

Ergotamine, headache, and COVID-19

1 26 Medical Center, Bangkok, Thailand
2 Department of Community Medicine, Dr. D. Y. Patil University, Pune, Maharashtra, India; Department of Tropical Medicine, Hainan Medical University, Haikou, China

Date of Submission15-Apr-2020
Date of Decision28-May-2020
Date of Acceptance13-Oct-2020
Date of Web Publication10-Feb-2023

Correspondence Address:
Dr. Rujittika Mungmunpuntipantip
26 Medical Center, Bangkok
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jdmimsu.jdmimsu_122_20

Rights and Permissions

How to cite this article:
Mungmunpuntipantip R, Wiwanitkit V. Ergotamine, headache, and COVID-19. J Datta Meghe Inst Med Sci Univ 2022;17:1023

How to cite this URL:
Mungmunpuntipantip R, Wiwanitkit V. Ergotamine, headache, and COVID-19. J Datta Meghe Inst Med Sci Univ [serial online] 2022 [cited 2023 Apr 1];17:1023. Available from: http://www.journaldmims.com/text.asp?2022/17/4/1023/369474


COVID-19 pandemic is a global public health problem. Medical professional has to recognize and adjust current medical practice to correspond to this emerging infectious disease. In clinical neurology, an important consideration is the use of drug for the management of patient. Of several problems, migraine is an important common medical disorder.

Silvestro et al. noted that a good plan for drug administration for controlling of migraine of the patients during the new disease outbreak was necessary.[1]

In clinical practice, a commonly used drug for the management of migraine is ergotamine. The interrelationship between ergotamine and COVID-19 is interesting. To clarify this issue, the authors hereby perform an interaction pathway analysis by standard bioinformatics technique as used in the previous study.[2] The interrelation analysis on the pharmacological pathway and pathogenesis pathway of coronavirus infection can show a common node at serotonin (5-HT) receptor. It seems that ergotamine might have unwanted effect against coronavirus [Figure 1]. In brief, ergotamine acts at the 5-HT 1B and 5-HT 1D receptors[3] and 5-HT signaling influences cellular activities that regulate the entry of coronavirus into cell.[4]
Figure 1: Interaction pathway analysis for ergotamine and coronavirus infection

Click here to view

Nevertheless, we would like to present additional data from only one from 2473 COVID-19 patients in Thailand (April 11, 2020) who have concurrent COVID-19 and migraine. In this case, ergotamine use did not cause any clinical problem (this case is still hospitalization).

The interrelationship between ergotamine, headache, and COVID-19 is an interesting topic for further research in clinical neurology.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Silvestro M, Tessitore A, Tedeschi G, Russo A. Migraine in the time of COVID-19. Headache 2020;60:988-9.  Back to cited text no. 1
Wiwanitkit V. Interaction between leptin and leptin receptor in gastric carcinoma: Gene ontology analysis. Rev Esp Enferm Dig 2007;99:201-5.  Back to cited text no. 2
Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: History, pharmacology, and efficacy. Headache 2003;43:144-66.  Back to cited text no. 3
Mainou BA, Ashbrook AW, Smith EC, Dorset DC, Denison MR, Dermody TS. Serotonin receptor agonist 5-nonyloxytryptamine alters the kinetics of reovirus cell Entry. J Virol 2015;89:8701-12.  Back to cited text no. 4


  [Figure 1]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article
Article Figures

 Article Access Statistics
    PDF Downloaded13    
    Comments [Add]    

Recommend this journal